Nikole Dahlke
Acute Care · Savannah, GANPI 1356936777
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,927 of the $6,252 with a category attached, or 62.8%. 23 manufacturers reported payments, led by Amgen at 38.2% of the total. Reporting peaked in 2024 at $3,450 and has fallen 53.6% since, to $1,602 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Travere Therapeutics, Inc.$736
- AstraZeneca$457
- Bayer$415
- Vifor Pharma, Inc.$357
- Mallinckrodt Hospital Products Inc.$308
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,40022%
- Speaking & faculty fees$5409%
- Food & beverage$3,92763%
- Education$3856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $2,386 |
| Travere Therapeutics, Inc. | 12 | $736 |
| AstraZeneca(2 entities) | 27 | $457 |
| Bayer | 23 | $415 |
| Vifor Pharma, Inc. | 12 | $357 |
| Mallinckrodt Hospital Products Inc. | 13 | $308 |
| Novartis | 18 | $302 |
| Otsuka America Pharmaceutical, Inc. | 9 | $189 |
| Corcept Therapeutics | 7 | $151 |
| Aurinia Pharma U.S., Inc. | 8 | $150 |
| Calliditas Therapeutics US Inc. | 7 | $138 |
| ANI Pharmaceuticals, Inc. | 6 | $109 |
| Fresenius USA Marketing, Inc. | 5 | $99 |
| OPKO Pharmaceuticals, LLC | 5 | $94 |
| Ardelyx, Inc. | 3 | $79 |
| Akebia Therapeutics Inc | 2 | $57 |
| Sanofi | 2 | $45 |
| GSK | 2 | $45 |
| Boehringer Ingelheim | 2 | $41 |
| Chiesi USA, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Boston Scientific | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$1,694
How this compares
$6,252 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 76 | $83,317 |
| KerendiaFinerenone | 50 | $58,139 |
| VeltassaPatiromer Calcium Sorbitex | 29 | $42,457 |
| VelphoroSucroferric Oxyhydroxide | 15 | $41,831 |
| AuryxiaFerric Citrate | 12 | $28,743 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $27,140 |
| Cinacalcet Hcl | 22 | $9,079 |
| Sevelamer Carbonate | 26 | $5,194 |
| Calcium Acetate | 22 | $2,797 |
| Nifedipine ErNifedipine | 86 | $1,718 |
| Losartan Potassium | 141 | $1,191 |
| Calcitriol | 27 | $989 |
| Bumetanide | 19 | $864 |
| Potassium Chloride | 25 | $719 |
| Midodrine Hcl | 11 | $684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $457 | $110,457113 claims |
| BayerKerendia | $415 | $58,13950 claims |
| Fresenius USA Marketing, Inc.Velphoro | $99 | $41,83115 claims |
| Akebia Therapeutics IncAuryxia | $57 | $28,74312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Savannah
- Stacy CreelSavannah$15K
- Beverly LippertSavannah$3K
- James HerringSavannah$3K
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.